Crystalline forms of N- {2-tert -butyl -1- [ (4,4dif luorocyclohexyl) methyl] - lH-benzimidazol-5yl}ethanesulfonamide salts

Details for Australian Patent Application No. 2007227811 (hide)

Owner AstraZeneca AB

Inventors Bohlin, Martin

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2007227811

PCT Pub. Number WO2007/108754

Priority 60/785,326 23.03.06 US

Filing date 22 March 2007

Wipo publication date 27 September 2007

International Classifications

C07D 235/08 (2006.01) Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings

A61K 31/4184 (2006.01)

A61P 1/00 (2006.01) Drugs for disorders of the alimentary tract or the digestive system

A61P 9/00 (2006.01) Drugs for disorders of the cardiovascular system

A61P 25/00 (2006.01) Drugs for disorders of the nervous system

A61P 25/16 (2006.01) Drugs for disorders of the nervous system

A61P 25/22 (2006.01) Drugs for disorders of the nervous system

A61P 25/28 (2006.01) Drugs for disorders of the nervous system

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

25 September 2008 PCT application entered the National Phase

  PCT publication WO2007/108754 Priority application(s): WO2007/108754

2 February 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007227813-Improved protofibril selective antibodies and the use thereof

2007227809-Fluorescence reader